Skip to main content
    • Aa
    • Aa

Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses

  • Juliano S Souza (a1) (a2), Monica Kayo (a1), Ivson Tassell (a1), Camila Bertini Martins (a3) and Helio Elkis (a1) (a2)...

Clozapine is considered the gold standard for the treatment of patients with treatment-resistant schizophrenia (TRS); however, randomized controlled trials (RCT) of olanzapine showed efficacy similar to clozapine in patients with TRS.


A systematic review was conducted comparing clozapine with olanzapine in patients with TRS. Meta-analyses were performed for single outcome measures. Response to treatment was measured by the percentage of responders, or mean change or endpoint values of psychotic symptoms scales. Effect sizes were shown as relative risks (RR), or standardized mean differences, with 95% confidence intervals.


Seven RCT were included, comprising 648 patients. Five meta-analyses were performed. Olanzapine and clozapine had similar effects on dropout rates (RR = 0.93, CI95% = 0.77–1.12), PANSS total endpoints (SMD = 0.21, CI95% = –0.04–0.46), and PANSS total mean changes (SMD = 0.08, CI95% = –0.01–0.027). Clozapine was superior to olanzapine for PANSS positive (SMD = 0.51, CI95% = 0.17–0.86) and negative (SMD = 0.50, CI95% = 0.16–0.85) subscales. There was a trend toward high doses of olanzapine producing higher effect sizes for this drug.


The results of this study suggest that clozapine is significantly more efficacious than olanzapine in improving positive and negative symptoms in TRS patients.

Corresponding author
*Address for correspondence: Juliano Santos Souza, University of São Paulo Medical School, Projesq–Schizophrenia Program, Rua Ovidio Pires de Campos 785, São Paulo SP-05403-010, Brazil. Email
Hide All

The authors would like to thank Dr. Carlos B. Pereira, Dr. Ricardo Moreno, and Dr. Orestes Forlenza for their valuable critical comments and suggestions for the manuscript, and also Carolina Rehem, for her library assistance.

Hide All
1.Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004; 363(9426): 20632072.
2.Meltzer H, Kostakoglu A. Treatment resistant schizophrenia. In: Liberman J, Murray R, eds. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management. London: Martin Dunitz; 2001: 181203.
3.Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2007; 30(3): 511533.
4.McEvoy J. The cost of schizophrenia. J Clin. Psychiatry. 2007; 68(suppl 14): 47.
5.Elkis H, Meltzer HY. [Refractory schizophrenia]. Rev Bras Psiquiatr. 2007; 29(Suppl 2): S41S47.
6.Brambilla P, Barale F, Caverzasi F, Tognoni G, Barbui C. Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. Int. Clin. Psychopharmcol. 2002; 17: 189195.
7.Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158: 518526.
8.Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60(6): 553564.
9.Essali A, Al-Haj H, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009: CD000059.
10.Leucht S, Corves C, Arbter D, etal. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 3141.
11.Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry. 2003; 183: 161166.
12.Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999; 156(7): 990999.
13.Sernyak MJ, Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr Serv. 2008; 59(5): 567569.
14.Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009; 39(10): 15911602.
15.Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, etal. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 7193.
16.Bondolfi G, Dufour H, Patris M, etal. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. the Risperidone Study Group. Am J Psychiatry. 1998; 155: 499504.
17.Breier A, Malhotra A, Su T, etal. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999; 156: 294298.
18.Asenjo Lobos C, Komossa K, Rummel-Kluge C, etal. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; (11): CD006633.
19.Leucht S, Komossa K, Rummel-Kluge C, etal. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166(2): 152163.
20.Lewis S, Barnes T, Davies L, etal. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006; 32: 715723.
21.McEvoy J, Lieberman J, Stroup T, etal. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006; 163: 600610.
22.Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008; 8: 3145.
23.Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004; 24(2): 192208.
24.Simpson GM, Josiassen RC, Stanilla JK, etal. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999; 156(11): 17441750.
25.Meltzer H, Bobo W, Roy A, etal. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008; 69(2): 274285.
26.Citrome L, Stauffer VL, Chen L, etal. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009; 29(3): 278283.
27.Kinon BJ, Volavka J, Stauffer V, etal. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008; 28(4): 392400.
28.Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011; 31(7): 455482.
29.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC: American Psychiatric Press; 1994.
30.Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261276.
31.Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10: 799812.
32.Guy W. Clinical Global Impression: ECDEU Assessment Manual for Psychopharmacology, Rev. ed.Rockville, MD: National Institutes of Mental Health; 1976: 218222.
33.Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Intervention. London: The Cochrane Collaboration; 2009.
34.Comprehensive Meta-Analysis. Englewood, NJ: Biostat. Available at Accessed August 2009.
35.Egger M, Smith GD, Altman DG, Eds. Systematic Reviews in Health Care. Meta-Analysis in Context. London: BMJ Books; 2001.
36.Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. The Psychiatrist. 1997; 21: 224226.
37.Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003; 64(6): 663667.
38.Azorin J, Spiegel R, Remington G, etal. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001; 158: 13051313.
39.Bitter I, Dossenbach M, Brook S, etal. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 28: 173180.
40.Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study. J Clin Psychopharmacol. 2003; 23(6): 668671.
41.Moresco R, Cavallaro R, Messa C, etal. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004; 18(3): 355365.
42.Naber D, Riedel M, Klimke A, etal. Randomized double blind comparison of olanzapine vs. clozapine on subjective wellbeing and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005; 111: 106115.
43.Sacchetti E, Galluzzo A, Valsecchi P, etal. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009; 110(1–3): 8089.
44.Tollefson G, Birkett M, Kiesler G, Wood A. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001; 49: 5263.
45.Volavka J, Czobor P, Sheitman B. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002; 159: 255262.
46.Fanous A, Lindenmayer J. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J Clin Psychopharmacol. 1999; 19: 275276.
47.Kumra S, Kranzler H, Gerbino-Rosen G, etal. Clozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008; 18(4): 307316.
48.Kumra S, Kranzler H, Gerbino-Rosen G, etal. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008; 63: 524529.
49.Launer M. Place of olanzapine in therapy. Pharmaceut J. 1998: 260267.
50.Lindenmayer J, Volavka J, Lieberman J, etal. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol. 2001; 21(4): 448453.
51.Mountjoy C, Baldacchino A, Stubbs J. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry. 1999; 156: 158159.
52.Reich J. Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry. 1999; 156: 661.
53.Sheitman B, Lindgren J, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry. 1997; 154(11): 1626 (letter).
54.Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006; 21(6): 393398.
55.Perry PJ, Argo TR, Carnahan RM, etal. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005; 25(3): 250254.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 8
Total number of PDF views: 125 *
Loading metrics...

Abstract views

Total abstract views: 663 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 24th October 2017. This data will be updated every 24 hours.